GlassScriptPhysician profile
David R Lichtinger
NPI 1124115027
$15,725.65
in general payments reported to CMS, 2019-2025
54 companies · $2,087 in 2025
The $2,087 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,033 · 2020: $2,145 · 2021: $2,685 · 2022: $2,584 · 2023: $2,028 · 2024: $2,165 · 2025: $2,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,205 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,204.70 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,348.16 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,494.28 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,395.28 | 2021-2025 | |
| Novo Nordisk INC | $1,077.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $776.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $677.64 | 2019-2025 | |
| Amgen INC. | $656.93 | 2019-2025 | Repatha, Otezla, Prolia |
| Novartis Pharmaceuticals Corporation | $606.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $528.98 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $463.94 | 2019-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $426.87 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $426.80 | 2019-2023 | |
| Allergan, INC. | $381.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $366.23 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $356.82 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lichtinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.